OTCBB ALERTS

[Mandroid]

IMGM Imagin Molecular Corporation announced today that the Company's wholly owned subsidiary
Imagin Nuclear Partners Corporation has purchased a Positron Emission
Tomography Camera from Positron Corporation for its initial joint
venture at a New York City medical center.
Imagin Nuclear Partners also announced it has commenced scanning
patients at a cardiac imaging center operating within the a New York
City medical center, pending the completion of formal definitive
agreements and the medical center's final consent and approval. "The
significance of this centers relationship is that it establishes
Imagin Nuclear Partners' business model as a leader in nuclear imaging
partnerships. Imagin Nuclear Partners plans to role out and replicate
coronary disease reversal and prevention centers through the thousands
of potential imaging partners across the North America," stated Joseph
Oliverio, Imagin's Chief Executive Officer. "We are excited to begin
patient scanning and look forward to formalizing our relationships."

About Imagin Molecular Corporation:

Imagin Molecular Corporation strategy and focus is dedicated to
business opportunities in positron emission tomography (PET)
manufacturing and the diagnosis of cancer, heart disease and
neurological diseases. PET is an advanced medical diagnostic imaging
procedure used by physicians in the detection of certain cancers,
coronary disease and neurological disorders including Alzheimer's
disease. Imagin Molecular Corporation has positioned the Company to be
a factor in PET and ancillary molecular imaging businesses. Imagin
Nuclear Partners, a wholly owned subsidiary of Imagin Molecular
Corporation, is a full-service joint venture molecular imaging partner
that will own, operate and administer out-patient medical diagnostic
imaging centers that utilizes PET and PET/CT scanning equipment.
Imagin Nuclear Partners specializes in using evidence based
bioinformatics specifically positioned in the market to provide the
maximal cost effective benefit to their joint venture partner and the
community. Imagin Molecular Corporation is also the Parent of Cipher
Multimedia a new Media Marketing and Distribution Solution Company
that provides a Distribution Solution for publishers of digital
content. Cipher Multimedia will develop marketing campaigns that will
assist Imagin, Positron Corporation and other companies market their
products and will continue to provide publishers a distribution
solution for digital content.

About Positron Corporation:

Positron Corporation designs, manufactures, markets and supports
advanced medical imaging devices utilizing positron emission
tomography (PET) technology under the trade name POSICAM(TM) systems.
POSICAM(TM) systems incorporate patented and proprietary software and
technology for the diagnosis and treatment of patients in the areas of
cardiology, oncology and neurology. Positron Corporation offers unique
combination of low cost technology and disease specific software
solutions differentiating themselves from all other medical device
manufacturers. POSICAM(TM) systems are in use at leading medical
facilities, including the University of Texas -- Houston Health
Science Center; The Heart Center of Niagara in Niagara Falls, New
York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in
Atlanta; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo.
Additional information may be found at http://www.positron.com/.

Forward Looking Statements

Certain statements in this release, and other written or oral
statements made by the Company, including the use of the words
"expect," "anticipate," "estimate," "project," "forecast," "outlook,"
"target," "objective," "plan," "goal," "pursue," "on track," and
similar expressions, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. These forward looking
statements are subject to known and unknown risks, uncertainties and
other factors that may cause actual results, performance, or
achievements of the company to be different from those expressed or
implied. The Company assumes no obligation and does not intend to
update these forward looking statements. Among the important factors
that could cause actual results to differ materially from those
indicated by such forward looking statements include, without
limitation: competitive and general economic conditions, adverse
effects of litigation, the timely development and acceptance of
services, significant changes in the competitive environment, the
failure to generate or the loss of significant numbers of customers,
the loss of senior management, increased government regulation or the
company's failure to integrate its acquired companies to achieve the
synergies and efficiencies described in the "Management's Discussion
and Analysis" section of the Company's Form 10-KSB and other reports
and filings with the Securities and Exchange Commission, which may be
revised or supplemented in subsequent reports on SEC Forms 10-QSB and
8-K.
For further information please contact Joseph Oliverio at Imagin
Molecular Corporation at 630 371 5583



KEYWORD: NORTH AMERICA ILLINOIS NEW YORK UNITED STATES
INDUSTRY KEYWORD: HEALTH CARDIOLOGY HOSPITALS MEDICAL DEVICES
SOURCE: Imagin Molecular Corporation


CONTACT INFORMATION:
Imagin Molecular Corporation
Joseph Oliverio, 630-371-5583